These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4872638)

  • 1. [Our experience with o,p'-DDD in the treatment of hypercorticism].
    Mathieu De Fossey B; Luton JP; Bricaire H
    Ann Endocrinol (Paris); 1968; 29(1):93-102. PubMed ID: 4872638
    [No Abstract]   [Full Text] [Related]  

  • 2. Remission in Cushing's syndrome with o,p'-DDD.
    Southren AL; Tochimoto S; Strom L; Ratuschni A; Ross H; Gordon G
    J Clin Endocrinol Metab; 1966 Mar; 26(3):268-78. PubMed ID: 4286017
    [No Abstract]   [Full Text] [Related]  

  • 3. A case of adrenocortical cancer treated with O,P'-DDD.
    Sakauchi N; Kumaoka S; Naruke T; Abe O; Kusama M
    Endocrinol Jpn; 1969 Apr; 16(2):287-90. PubMed ID: 5819718
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment with o,p'-DDD of inoperable forms of malignant adrenal gland neoplasms].
    Perevodchikova NI; Platinskiĭ LV; Kertsman VI
    Vopr Onkol; 1972; 18(11):24-9. PubMed ID: 4645074
    [No Abstract]   [Full Text] [Related]  

  • 5. [Inhibition of adrenocortical steroid production in therapy].
    Bricaire H; Philbert M; Luton JP
    Rev Fr Etud Clin Biol; 1968; 13(6):563-7. PubMed ID: 4178146
    [No Abstract]   [Full Text] [Related]  

  • 6. Suppression of tumorous adrenal hyperfunction by aminoglutethimide.
    Smilo RP; Earll JM; Forsham PH
    Metabolism; 1967 Apr; 16(4):374-7. PubMed ID: 4290376
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of DL-2(p-aminophenyl)-2-phenylethylamine on adrenocortical function in Cushing's syndrome due to nontumorous adrenocrotical hyperfunction.
    Gabrilove JL; Nicolis GL; Gallagher TF
    J Clin Endocrinol Metab; 1967 Nov; 27(11):1550-7. PubMed ID: 6075585
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical application of o.p' DDD to the case of adrenal cortex cancer].
    Naruse T; Sasaki T; Yamaoka T; Matsuoka K; Nekita H
    Horumon To Rinsho; 1970 Mar; 18(3):241-4. PubMed ID: 5464572
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical and biological study of an inhibitor of adrenocortical hormone synthesis: aminoglutethinide].
    Philbert M; Laudat MH; Laudat P; Bricaire H
    Ann Endocrinol (Paris); 1968; 29(2):189-210. PubMed ID: 4298418
    [No Abstract]   [Full Text] [Related]  

  • 10. Metastatic adrenal cortical carcinoma: biochemical changes accompanying clinical regression during therapy with o,p'-DDD.
    Helson L; Wollner N; Murphy ML; Schwartz MK
    Clin Chem; 1971 Dec; 17(12):1191-3. PubMed ID: 4330217
    [No Abstract]   [Full Text] [Related]  

  • 11. Steroids in urine from a patient with adrenocortical carcinoma after treatment with op'-DDD.
    Gustafsson JA; Lisboa BP
    Steroidologia; 1971; 2(1):27-37. PubMed ID: 5133742
    [No Abstract]   [Full Text] [Related]  

  • 12. Hormone-secreting tumors of the adrenal cortex in children.
    Hayles AB; Hahn HB; Sprague RG; Bahn RC; Priestley JT
    Pediatrics; 1966 Jan; 37(1):19-25. PubMed ID: 4285417
    [No Abstract]   [Full Text] [Related]  

  • 13. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients.
    Hutter AM; Kayhoe DE
    Am J Med; 1966 Oct; 41(4):581-92. PubMed ID: 5923599
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of aminoglutethimide upon adrenal function and cortisol metabolism in Cushing's syndrome.
    Schteingart DE; Conn JW
    J Clin Endocrinol Metab; 1967 Dec; 27(12):1657-66. PubMed ID: 6060954
    [No Abstract]   [Full Text] [Related]  

  • 15. Testosterone and androstenedione production rates in patients with metastatic adrenal cortical carcinoma.
    Bardin CW; Lipsett MB; French AM
    J Clin Endocrinol Metab; 1968 Feb; 28(2):215-20. PubMed ID: 5636152
    [No Abstract]   [Full Text] [Related]  

  • 16. Malignant melanoma with ectopic production of adrenocorticotropic hormone. Palliative treatment with inhibitors of adrenal steroid biosynthesis.
    Carey RM; Orth DN; Hartmann WH
    J Clin Endocrinol Metab; 1973 Mar; 36(3):482-7. PubMed ID: 4119547
    [No Abstract]   [Full Text] [Related]  

  • 17. Medical treatment of canine hyperadrenocorticoidism with o,p'-DDD.
    Lorenz MD; Scott DW; Pulley LT
    Cornell Vet; 1973 Oct; 63(4):646-65. PubMed ID: 4748884
    [No Abstract]   [Full Text] [Related]  

  • 18. Diagnostic and therapeutic problems in spontaneous Cushing's syndrome. A review with five case reports.
    Poulsen JE; Asfeldt VH
    Scand J Urol Nephrol; 1972; 6():Suppl 15:89-96. PubMed ID: 4644112
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of d-2(p-aminophenyl)-2-phenylethylamine (SK&F-12185) in Cushing's syndrome associated with adrenocortical carcinoma.
    Gabrilove JL; Nicolis GL; Gallagher TF
    Metabolism; 1968 Oct; 17(10):936-42. PubMed ID: 4877990
    [No Abstract]   [Full Text] [Related]  

  • 20. [The use of modified stimulation test in the diagnosis of adrenal cortex diseases].
    Konopka P; Morawek A; Religa Z
    Pol Arch Med Wewn; 1969 Jul; 43(1):1025-34. PubMed ID: 4310037
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.